We have identified a mouse PDZ protein that interacts with the activin type IIA receptor (ActRIIA), which we named activin receptor-interacting protein 1 (ARIP1). By using yeast two-hybrid screening, we isolated a cDNA clone of ARIP1 from a mouse brain cDNA library. We detected two forms of ARIP1, ARIP1-long and ARIP1-short, which may be produced by alternative splicing. ARIP1-long had one guanylate kinase domain in the NH 2 -terminal region, followed by two WW domains and five PDZ domains (PDZ1-5). ARIP1-short had a deletion in the NH 2 -terminal region and lacked the guanylate kinase domain. Both forms interacted with ActRIIA through PDZ5. The COOH-terminal residues of ActRIIA (ESSL) agree with a PDZ-binding consensus motif, and ARIP1 recognized the consensus sequence. ARIP1 interacts specifically with ActRIIA among the receptors for the transforming growth factor ␤ family. Interestingly, ARIP1 also interacted with Smad3, which is an activin/ transforming growth factor ␤ intracellular signaling molecule. The mRNA of ARIP1 was more abundant in the brain than in other tissues. Overexpression of ARIP1 controls activin-induced and Smad3-induced transcription in activin-responsive cell lines. These findings suggest that ARIP1 has a significant role in assembling activin signaling molecules at specific subcellular sites and in regulating signal transduction in neuronal cells.
Activin is a multifunctional growth and differentiation factor that belongs to the transforming growth factor-␤ (TGF-␤) 1 superfamily. Activin has numerous biological activities: regulation of secretion of follicle-stimulating hormone from pituitary cells (1, 2) , stimulation of differentiation of erythroblasts (3) , and mesoderm induction in Xenopus embryos (4) . Activin has also been reported to act on neural cells. Activin is a survival factor for neural cells derived from rat brain (5) , regulates neuronal development in the avian iris and ciliary body (6) , and regulates expression of neuropeptides by cultured sympathetic neurons (7) .
Activin signals through two types of membrane-bound receptor complexes on the target cells (8 -10) . Two types of activin receptor have been identified, type I and type II, both of which belong to the family of serine/threonine kinase receptors. Interaction between the type I and type II receptors is necessary for activin-induced signal transduction. Activin binds directly to the type II receptor, which then recruits the type I receptor to the complex and phosphorylates it, resulting in the activation of the type I receptor and in the downstream propagation of the signal (11) . There are two subtypes of the type II activin receptor, types IIA (ActRIIA) and IIB (ActRIIB), which are encoded by individual genes. In addition, two splice variants of ActRIIA including ActRIIA-N (12, 13) and five splice variants of ActRIIB have been reported (14, 15) . We have previously shown that ActRIIA-N is expressed specifically in neural tissues (13) . Although our understanding of activin/TGF-␤ signaling pathways has progressed during past few years (16) , the significance of the various type II activin receptors is not known. Recent investigations have suggested that signal transduction via transmembrane receptors is regulated by PDZ domain-containing molecules that interact with the receptors. Many PDZ domain-containing proteins have a role in assembling receptors and signaling molecules in the cell membrane and in submembranous regions.
To determine the specific functions of the activin type IIA receptors in activin signal transduction, we searched for cytoplasmic proteins that interact with these receptors. We identified a novel cytoplasmic protein, which we named activin receptor-interacting protein 1 (ARIP1), that is abundant in the brain. ARIP1 had multiple protein-protein interaction domains, including two WW domains and five PDZ domains, and it interacted with Smad3 as well as with ActRIIA and ActRIIA-N.
Thus, ARIP1 is a scaffolding protein that unites activin receptors with an intracellular signaling molecule (Smad) and thereby regulates activin-mediated signaling in neuronal cells.
EXPERIMENTAL PROCEDURES
cDNA Cloning-Yeast two-hybrid screening was performed using a commercially available system (Matchmaker Two-Hybrid System 2; CLONTECH) according to the manufacturer's protocol. Approximately 4 ϫ 10 6 clones of a mouse brain cDNA library (CLONTECH) were screened using a bait construct, pAS-ActRIIA-N, that contained the nucleotide sequences for the entire cytoplasmic region of mouse ActRIIA-N fused to a GAL4 DNA-binding domain.
To obtain a full-length clone for ARIP1, a mouse brain cDNA library in the ZAPII vector (STRATAGENE) was screened using the insert of #YN3 as the probe. One clone encoding the full-length of the ARIP1-short sequence was identified.
A cDNA encoding ARIP1-long was obtained by joining the ARIP1-short cDNA and the PCR-derived NH 2 -terminal sequence. Reverse transcription-PCR was performed using a sense primer synthesized according to the rat S-SCAM sequence (nucleotides 30 -49, 5Ј-agagaaaggcaaagtctgcc-3Ј; Ref. 20) and an antisense primer based on the mouse ARIP1-short sequence (nucleotides 1117-1140, 5Ј-gtagctcccggaagtatctggtct-3Ј). The amplified products were cloned into pUC19, sequenced, and ligated to the ARIP1-short cDNA.
DNA Constructs-DNA constructs for yeast two-hybrid screening were made using the plasmid pAS2-1 to express the fusion protein with the GAL4 DNA-binding domain, and the plasmid pACT2 was used to express the fusion protein with the GAL4 activation domain. pASActRIIA and pAS-ActRIIA-N were made by introducing nucleotides 554 -1995 of mouse ActRIIA (12) or nucleotides 554 -2019 of ActRIIA-N (13) into pAS2-1. An insert fragment of pACT2-ARIP1-long was made by ligating a PCR-amplified fragment that contained the translational start methionine codon to a KpnI/EcoRV fragment (nucleotides 1071-4446) of the ARIP1-short cDNA. pACT2-ARIP1-short was made by introducing nucleotides 1187-4446 of pBS-ARIP1-short into pACT2. A series of deletion mutants was made by combining PCR-generated fragments and fragments prepared from pBS-ARIP1-short. pAS-⌬Guk-PDZ2 contained nucleotides 2830 -4446, pAS-⌬Guk-PDZ4 contained nucleotides 3826 -4446, pAS-⌬PDZ5 contained nucleotides 923-3825, pAS-⌬PDZ3-5 contained nucleotides 923-2814, and pAS-⌬PDZ1-5 contained nucleotides 923-1725.
DNA constructs for the mammalian two-hybrid assay were made as follows using the plasmid pBIND to express the fusion protein with the GAL4 DNA-binding domain and using pACT to express the fusion protein with the VP16 activation domain. To make pBIND-ActRIIA and pBIND-ActRIIA-N, cDNA fragments encoding the entire cytoplasmic regions of pAS-ActRIIA and pAS-ActRIIA-N were subcloned into pBIND. Mutations in the COOH terminus of ActRIIA were generated by replacing the appropriate nucleotides with mutated oligonucleotides by PCR-based mutagenesis. To make other receptor constructs, the following sequences, which contain the entire cytoplasmic region of each receptor, were amplified by PCR and cloned into the BamHI/SalI site of pBIND: mouse ActRIIB, nucleotides 524 -1654 (14) ; human TGF-␤ type II receptor, nucleotides 568 -1698 (21); and human bone morphogenetic protein type II receptor, nucleotides 679 -1755 (22) . To make pACT-ARIP1, a cDNA fragment composed of nucleotides 923-4446 of ARIP1, which was prepared by ligating a PCR-generated fragment to a fragment prepared from pBS-ARIP1-short, was subcloned into pACT. ARIP1-short was used throughout the experiment, whereas ARIP1-long was only used in the experiment shown in Fig. 2A . pACT-ARIP1 (WW), which lacked all of the PDZ domains, contained nucleotides 923-1758 of ARIP1. To make pBIND-Smad3, human Smad3 coding sequences were ligated to pBind.
An expression construct of ARIP1 for transcriptional assay was made by subcloning nucleotides 923-4446 of ARIP1 into pcDNA1. FLAGtagged Smad3 and Smad6 in pcDNA3 were generous gifts from Dr. K. Miyazono. Smad7 in pcDNA3 was obtained from Dr. P. ten Dijke.
The 5Ј junctional region between the insert and the vector of each construct was sequenced to ensure that the inserts were introduced properly.
Yeast and Mammalian Two-hybrid Assay-Yeast two-hybrid assay was performed using a commercially available kit (Matchmaker TwoHybrid System 2; CLONTECH) according to the manufacturer's protocol.
Mammalian two-hybrid assay was performed using CheckMate Mammalian Two-Hybrid System (Promega), according to the manufacturer's protocol. In brief, CHO cells were cotransfected with the plasmids of interest, a cytomegalovirus promoter-driven ␤-gal (CMV-␤-gal) and a reporter plasmid, pG5luc, which drives the luciferase gene under the control of GAL4-responsive promoter (18) . Luciferase activity was measured and normalized to the ␤-galactosidase activity as described previously (8) .
Immunoprecipitation and Western Blotting-The interaction of fulllength ARIP1 and ActRIIA and that of full-length ARIP1 and Smad3 in mammalian cells were studied. COS7 cells were cotransfected with either pcDLSR␣-ActRIIA (17) and CMV-FLAG-ARIP1, or with CMV6Myc-ARIP1 and CMV-FLAG-Smad3, by the calcium phosphate precipitation method. Two days after transfection, the cells were incubated in a lysis buffer (1% Nonidet P-40, 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 4 g/ml leupeptin, and 1 g/ml aprotinin). The lysate was centrifuged, and the proteins were immunoprecipitated by adding anti-FLAG monoclonal antibody (M2; Sigma) or anti-Myc monoclonal antibody (9E10; Oncogene), and then the samples were incubated with protein A-Sepharose (Amersham Pharmacia Biotech) for 2 h at 4°C. The precipitated proteins were fractionated by SDS-PAGE, and transferred onto a polyvinylidene difluoride membrane. Then the membranes were incubated with an antiActRIIA or an anti-FLAG antibody (diluted 1:1000), followed by incubation with a horseradish peroxidase-conjugated second antibody. Labeled proteins were detected by chemiluminescence (ECL-Plus; Amersham Pharmacia Biotech).
Affinity Labeling-Cotransfected COS-7 cells were affinity-labeled with 125 I-activin A, 2 days after transfection. Radiolabeling of the ligand, affinity cross-linking, and preparation of cell lysates were performed as described previously (19) . Cell lysates were incubated with an anti-Myc monoclonal antibody (9E10) or an anti-FLAG monoclonal antibody (M2; Sigma) for 1 h at 4°C, and then the samples were incubated with protein A-Sepharose beads (Amersham Pharmacia Biotech) for 2 h at 4°C. Then the beads were washed three times with a lysis buffer. Then precipitated proteins were fractionated by SDS-PAGE and detected by autoradiography.
Northern Blotting-Poly(A)ϩ RNAs were prepared from various tissues of Balb/c strain mice. RNA (1 g) from each sample was fractionated and blotted onto a nylon membrane. A mixture of three cDNA fragments of pBS-ARIP1-short (nucleotides 1-1391, 1772-3202, and 3356 -4440) labeled with digoxigenin-11-dUTP (Roche Molecular Biochemicals) by PCR was used as probes. Hybridization, washing, and detection were performed as described previously (23) .
Activin-responsive Promoter Assay-The p3TP-lux construct has been described previously (8) . p3TP-lux, CMV-␤-gal, and either pcDNA1-ARIP1 or CMV-FLAG-Smad3 were introduced into human K562 cells by eletroporation. Mouse hippocampus-derived HT22 cells (obtained from Dr. D. Shubert, The Salk Institute) were transfected with p3TP-lux, CMV-␤-gal, and combinations of CMV-FLAG-Smad3 and/or pcDNA1-ARIP1 by using TransFast liposome reagents (Promega) according to the manufacturer's protocol. Stimulation by activin and measurement of luciferase activity were performed as described previously (8) .
Antibody Production and Immunohistochemistry on Cultured Hippocampal Neurons-For anti-ARIP1 antibodies, GST fusion proteins of N-terminal ARIP1 (nucleotides 923-1758) were purified and used for immunization of New Zealand White rabbits. ARIP1-specific antisera were purified by passing through protein A-Sepharose and were used for immunohistochemistry.
Rat hippocampal neuronal cultures were prepared from E18 embryonic rats as described (24) . Neuronal cells cultured on poly-L-lysinecoated coverslips were fixed by incubation with 4% paraformaldehyde for 10 min at room temperature, followed by incubation in ice-cold 100% methanol for 5 min. Cells were visualized by immunostaining using rabbit anti-ARIP1 antibody (1:200 dilution), or rabbit anti-ActRIIA antibody (1:200 dilution), or goat anti-Smad2/3 antibody (1:100 dilution, clone E-20 purchased from Santa Cruz). All cells were costained with mouse anti-synaptotagmin I monoclonal antibody (1;400 dilution, mAb1D/2 kindly provided by Dr. M. Takahashi at the Mitsubishi Kasei Institute of Life Scieices) (25) . Then, the cells were incubated with fluorescein-conjugated secondary antibody at a 1:400 dilution (Alexa 488 for staining ARIP1, ActRIIA, and Smad2/3 and Alexa 594 for staining synaptotagmin I). Fluorescent images of cells were captured by using a confocal microscope (Leica TCS-NT).
RESULTS
Cloning of ARIP1-In order to investigate intracellular proteins interacting with activin type IIA and/or IIA-N receptors (ActRIIAs), we used yeast two-hybrid system. By screening a library of mouse brain cDNAs fused to the GAL4 activation domain using ActRIIA-N fused with GAL4 DNA-binding domain as a bait, we obtained about 60 positive clones, which we classified into five groups based on restriction fragment analysis. Clones with the longest inserts were selected from each group and were tested for interaction with ActRIIAs in mammalian cells. ActRIIA and candidate clones with the NH 2 -terminal Myc-epitope in an SR␣ expression vector were cotransfected in COS-7 cells and the proteins in the cell lysates were immunoprecipitated using an anti-Myc antibody. Only one clone (#YN3) was co-precipitated by ActRIIAs (data not shown). #YN3 contained a 1140-bp insert and encoded one PDZ domain (Fig. 1B) . By screening another mouse brain cDNA library using the insert of #YN3 as the hybridization probe, we obtained a full-length cDNA clone of ARIP1-short (pBS-ARIP1-short, Fig. 1A ). The ARIP1-short cDNA encoded a protein of 1112 amino acids, which has two WW domains in the NH 2 -terminal region, followed by five PDZ domains. #YN3 encoded 228 amino acids, including the entire PDZ5 domain; however, the sequence of #YN3 did not match that of ARIP1 exactly in the COOH-terminal region. The NH 2 -terminal 213 amino acids of #YN3 were identical to amino acid residues 853-1065 of ARIP1-short, but #YN3 had 15 additional amino acids (AFHS-FLHLCSAFSVF) that were not in the ARIP1-short sequence.
During the course of this study, Hirao et al. (20) reported the amino acid sequence of a rat homologue of ARIP1, which they named S-SCAM (synaptic scaffolding molecule). S-SCAM is 98.7% identical to the sequence of ARIP1-short when the NH 2 -terminal region is excluded from the analysis; S-SCAM has an additional 163 NH 2 -terminal amino acids compared with ARIP1-short. The additional 163 amino acids includes a guanylate kinase domain (Guk). We also detected a long form of ARIP1 in mouse brain by reverse transcription-PCR using a primer synthesized according to the rat S-SCAM sequence, which had the same NH 2 -terminal sequence as S-SCAM. However, all of the clones we obtained by screening two independent libraries, including two clones from a mouse brain library and 12 clones from a rat brain library, encoded ARIP1-short (data not shown). Thus, it is likely that the short form is more abundant than the long form in mammalian brains. There is an in-frame stop codon 78 base pairs upstream from the boundary site between the long and short form sequences, and those 78 base pairs do not include a start codon. Therefore, we think that translation starts from the first methionine (Fig. 1A) , because this is the first methionine after the stop codon and transcription would then be of the longest reading frame. However, we cannot rule out the possibility that the methionine at amino acid position 60 is the translation start site because the nucleotide sequence near Met-60 agrees well with Kozak's consensus sequences (26) .
ARIP1 Interacted with COOH-terminal Amino Acids of ActRIIAs through PDZ5-ARIP1 interacted with both ActRIIA and ActRIIA-N (Fig. 2, A-C) . Deletion from the NH 2 terminus to PDZ4 of ARIP1 did not affect its interaction with ActRIIAs ( Fig. 2A) . On the other hand, the construct encoding only PDZ5 was able to interact with ARIP1, and deletion of PDZ5 from ARIP1 resulted in the complete loss of interaction with ActRIIA or ActRIIA-N. These results indicate that ARIP1 interacts with ActRIIA and ActRIIA-N through PDZ5.
Previously characterized PDZ domains recognize a class I consensus PDZ-binding motif, XSX(V/I/L) (where X is any amino acid), at the COOH terminus of the target proteins (27, 28) . The four COOH-terminal amino acids of ActRIIAs are ESSL, which agrees with the consensus PDZ-binding sequence. In the present study, ARIP1 did not interact with mutated ActRIIA proteins that lacked either the COOH-terminal SSL or the COOH-terminal leucine (Fig. 2B) . Thus, the COOH-terminal amino acids of the receptors play a central role in the interaction of ARIP1 with ActRIIAs through PDZ5.
ARIP1 Interacts Specifically with ActRIIAs among the Serine/Threonine Kinase Receptors in Mammalian Cells-ARIP1
did not interact significantly with ActRIIB, bone morphogenetic protein type II receptor, or the TGF-␤ type II receptor in the mammalian two-hybrid system (Fig. 2C) . In addition, ARIP1 did not interact with ActRIA and ActRIB in the yeast system (data not shown). These results indicate that ARIP1 interacts specifically with ActRIIA and ActRIIA-N among the serine/threonine kinase receptors for the TGF-␤ family and that this interaction can occur in both yeast cells and mammalian cells. When lysates of ActRIIA and FLAG-tagged ARIP1 cotransfected COS7 cells were incubated with an anti-FLAG antibody, the immunoprecipitated protein was detected by an anti-ActRIIA antibody, which confirmed that ActRIIA and ARIP1 formed a protein complex in the transfected cells (Fig.  2D) .
ARIP1 Interacted Directly with Smad3 as Well as with ActRIIAs in Mammalian
Cells-Because many PDZ domain-containing proteins have a role in assembling receptors and signaling molecules in the cell membrane and in the submembranous region, we next investigated the interaction of ARIP1 with an intracellular signaling molecule Smad in mammalian cells. Smads are classified into 3 groups, signal-specific Smads (Smad2 and Smad3 for activin and TGF-␤ and Smad1, Smad5, and Smad8 for bone morphogenetic proteins), commonmediator Smad (Smad4), and inhibitory Smads (Smad6 and Smad7). Among them, Smad3 is shown to transiently associate with activin type IB and TGF-␤ type I receptor and to be phosphorylated by the type I receptors to propagate downstream signaling (29) . We observed a specific interaction between Smad3 and ARIP1 in CHO cells transfected with a full-length Smad3 cDNA fused to the GAL4 DNA-binding domain and ARIP1 fused to the VP16 activation domain in the mammalian two-hybrid system (Fig. 3A) . Because Smad3 does not contain a consensus PDZ-binding sequence in its COOHterminal region, it is likely that Smad3 associates with ARIP1 through a region other than PDZ domains. As expected, Smad3 interacted with an ARIP1 mutant that lacked all five PDZ domains but retained the WW domains (Fig. 3A) . The direct interaction of the FLAG-Smad3 and Myc-ARIP1 in transfected COS-7 cells was confirmed by immunoprecipitation with an anti-FLAG antibody, followed by blotting with an anti-Myc antibody (Fig. 3B) . Smad2 also interacted with ARIP1 but not as strongly as did Smad3 (data not shown). To detect the association of ARIP1 and Smad3 in the activin receptor complex in the presence of ligand, affinity labeling with 125 I-activin A was performed. When COS-7 cells cotransfected with ActRIIA, ActRIB(K234R) (8), 6Myc-ARIP1, and FLAG-Smad3 were incubated in the presence of 125 I-activin A, the 125 I-labeled receptor complex could be precipitated by either of the anti-Myc and anti-FLAG antibodies (Fig. 3C) .
Therefore, ARIP1 is capable of forming a complex with ActRIIA, ActRIB, and Smad3 in the presence of ligand.
ARIP1 mRNA Was Predominantly Expressed in Neuronal Tissues-Northern blots of poly(A)ϩ RNA extracted from several mouse tissues showed ARIP1 mRNA of approximately 7.5 and 6.5 kilobases. Both bands were distinct in the brain and faint in the heart and testis (Fig. 4) . Thus, ARIP1 mRNA is more abundant in neuronal tissues than in other tissues. The two mRNA species seen in the Northern blot probably reflect differences in the 3Ј-noncoding regions, because two groups of cDNAs isolated by cloning had 3Ј-noncoding regions of different lengths.
ARIP1 Regulated Activin-and Smad3-induced Transcription-Human K562 erythroleukemia cells, the proliferation and differentiation of which are regulated by activin, were transfected with pcDNA1-ARIP1 together with a reporter plasmid p3TP-lux, and activin-induced luciferase activity was measured. Overexpression of ARIP1 by transfected K562 cells decreased the activin-induced transcriptional activity in a dosedependent manner (Fig. 5A) . However, Smad7, which is a potent negative regulator of intracellular signal transduction by lanes 1-3) , or COS 7 cells transfected with pcDLSR␣-ActRIIA, CMVActRIB(K234R), CMV-6Myc-ARIP1, and CMV-FLAG-Smad3 (lanes 4 -6) were incubated with 2 nM 125 I-activin A and cross-linked with disuccinimidyl suberate. Proteins in the detergent solubilized fraction were immunoprecipitated (IP) using an anti-FLAG antibody (lanes 2 and 5) or an anti-Myc antibody (lanes 3 and 6) and fractionated by SDS-PAGE under reducing conditions. In lanes 1 and 4, total lysates were analyzed. The positions of type I and type II activin receptors are indicated on the left. Molecular weight markers are indicated on the right.
activin and TGF-␤, inhibited the activin-induced transcriptional induction more potently than did ARIP1. Inhibition by ARIP1 was comparable with that of Smad6, which is also an inhibitory Smad for TGF-␤ and bone morphogenetic proteins. Because ARIP1 is predominantly expressed in neuronal tissues and has been suggested to have a role in synaptic transmission in the hippocampus and other brain regions (20), we have investigated the effects of ARIP1 in activin signaling in hippocampus-derived cell line, HT22, which expresses ARIP1 endogenously (30) (data not shown). Activin induced a 3TP-lux transcriptional response in HT22 cells (Fig. 5B) . Although overexpression of ARIP1 barely affected the response to activin, it did significantly suppress Smad3-induced augmentation of the transcriptional response to activin (Fig. 5B) . Because ARIP1 is capable of binding Smad3 (Fig. 3) , it seems likely that ARIP1 bound Smad3 in the HT22 cells and thus prevented Smad3 to exert transcriptional response in the nucleus.
ARIP1 Colocalized with ActRIIA and Smad3 in Rat Hippocampus Primary Neurons-In order to investigate the cellular localization of ARIP1 protein, rabbit polyclonal antisera were prepared and were used for immunohistochemistry in cultured rat hippocampal primary neurons. As shown in Fig. 6 , A-C, double-immunostaining of hippocampal cells by ARIP1 and synaptotagmin I antibodies showed that ARIP1 immunoreactivity is present primarily in neurons, especially in synaptic areas. Costained images were also obtained when cells were double-immunostained either by ActRIIA and synaptotagmin I antibodies (Fig. 6, D-F) or by Smad 2/3 and synaptotagmin I antibodies (Fig. 6, G-I) , suggesting that ARIP1 colocalizes with ActRIIA and Smad3 in hippocampal neurons. DISCUSSION We have isolated and characterized a mouse PDZ protein, which we named ARIP1, that interacts with ActRIIA and Act-RIIA-N. This is the first report of a molecule that associates with type II activin receptors, although a WD-domain-containing protein (TRIP1) that interacted with the TGF-␤ type II receptor has been reported (31) . We detected two forms of ARIP1, ARIP1-long and ARIP1-short, which differed in their NH 2 -terminal sequences. Each form interacted with both ActRIIA and ActRIIA-N. Recently, the rat and human homologues of the mouse ARIP1 gene have been found. The rat protein, called S-SCAM, is a scaffolding synaptic molecule that interacts with N-methyl-D-aspartate (NMDA) receptors (20) . The human homologue, called AIP1, associates with atrophin, which is responsible for the pathogenesis of CAG triplet disease, called dentatorubral-pallidoluysian atrophy (32) . cDNAs for S-SCAM and AIP1 encode proteins that correspond to ARIP1-long. In the present study, ARIP1-long was detected only by reverse transcription-PCR and all of the cDNA clones obtained by library screening, which covered the entire proteincoding region, encoded ARIP1-short. Therefore, ARIP1-short seems to be the major mRNA species in mammalian brain. The isoforms of ARIP1 are probably produced by alternative splicing, because their nucleotide sequences are dissimilar from the junction site to the 5Ј end. The inconsistency observed in 3Ј region of #YN3 and ARIP1-short appears to have been produced by alternative splicing as well, because their cDNA sequences are dissimilar from the junction site to the 3Ј end.
A mouse protein called MAGI-1 has a domain organization similar to that of ARIP1 (33) , which suggests that the genes encoding these two proteins belong to the same gene family.
Our analysis of the interactions between mutant ARIP1 proteins and ActRIIA showed that ARIP1 interacts with the COOH terminus of ActRIIAs mainly via the PDZ5 domain. The three COOH-terminal amino acids of ActRIIAs, which are consistent with the consensus PDZ-binding motif, were critical for this interaction (Fig. 2B) . The PDZ5 domain of ARIP1 seemed to prefer leucine to isoleucine in the COOH terminus of the target protein; we did not detect significant interaction between ARIP1 and ActRIIB, which has the COOH-terminal sequence ESSI. On the other hand, S-SCAM was originally cloned by its activity to bind to a postsynaptic protein, SAPAP (SAP90/postsynaptic density-95-associated proteins), through a Guk domain. In addition, S-SCAM interacts with the COOH termini of the 2A and 2C subunits of NMDA receptors (NR2A and NR2C) through PDZ5 (20) . The COOH-terminal sequences of NR2A and NR2C are ESDV and ESEV, respectively, which are consistent with the consensus PDZ-binding motif. Whether ActRIIA and the NMDA receptors associate with ARIP1 cooperatively or compete with each other remains to be determined.
Interestingly, ARIP1 associated with Smad proteins. The WW domains of ARIP1 interacted with Smad3 specifically (Fig.  3A) . WW domains prefer to bind to a proline-rich sequence, called the PY motif (PPXY) (34) , and Smad proteins have a PY motif in the linker region (29) , so it makes sense that ARIP1 and Smad3 interacted. Smad3 associates transiently with and is phosphorylated by activated ActRIB and by the TGF-␤ type I receptor, which triggers intracellular signaling. Because different domains of ARIP1 are responsible for its association with ActRIIA and with Smad3 (Fig. 3) , a quaternary complex of ActRIIA, ActRIB, Smad3, and ARIP1 can form. Thus, the biological function of ARIP1 is likely to be the assembly of a macromolecular structure composed of two types of activin receptor and an intracellular signaling molecule for activin signal transduction in the cell membrane and in the submembranous region. The way of ARIP1 assembles membrane proteins is reminiscent of the Drosophila PDZ protein, InaD. InaD, which has multiple PDZ domains, acts as a scaffold for rhodopsin, a calcium channel, protein kinase C, and phospholipase C in phototransduction cascades (35) . Recently, a protein that has an FYVE-domain, called SARA (Smad anchor for receptor activation), was identified in a study of TGF-␤ signaling. SARA associates with TGF-␤ receptors and Smad and regulates TGF-␤ signaling (36) . Because SARA and ARIP1 do not show any structural similarities, these proteins probably regulate receptor serine/threonine kinases in different ways.
We have shown that ARIP1 mRNA is abundant in mouse brain, and we also detected low amounts of ARIP1 in kidney, lung, heart, and testis. Therefore, ARIP1 is predominantly expressed in brain compared with the other tissues.
Overexpression of ARIP1 reduced activin-induced transcription in human K562 cells (Fig. 5A ) and suppressed Smad3-augmented transcription in a mouse hippocampus-derived HT 22 cells (Fig. 5B) ; thus, ARIP1 may regulate activin-induced signaling in neuronal cells. Whether ARIP1 inhibits signal transduction under physiological conditions remains to be determined; nevertheless, it is a fascinating idea that ARIP1 could be involved in the activation and/or deactivation of activin signaling in neuronal cells, like InaD in the phototransduction cascade (37) . ARIP1 has multiple protein-protein inter- action domains and can recruit Smad3 as well as binding to activin receptors; thus, ARIP1 may be the scaffold of the activin-signaling complex in the cell membrane and in the submembranous region and participate in a physiological regulation of signal transduction.
S-SCAM, the rat homologue of ARIP1, binds the postsynaptic protein SAPAP; thus, it may have a role in synaptic transmission (20) . The postsynaptic membrane has a dense thickening of submembranous cytoskeleton, called postsynaptic density, that is essential for the localization of neurotransmitter receptors and ion channels. SAPAP is thought to have a central role in the formation of postsynaptic density (38) . S-SCAM also interacts with the other postsynaptic density components, including NMDA receptor subunits and a neuronal cell adhesion molecule, neuroligin-1 (20) .
The emergence of adapter and scaffolding proteins as critical functional elements of cellular signaling processes suggests that an important principle of signal transduction lies in the spatial organization of transmembrane receptors and ion channels. ARIP1 (S-SCAM) must be one of the molecules responsible for the macromolecular organization of signaling components in neuronal cells.
Activins and their receptors were first characterized as essential regulatory molecules of the hypothalamus-pituitarygonadal axis. However, recent investigations have shown that activins also have roles in nervous system organization. Expression of mRNA for the activin ␤A subunit increases in the hippocampus during long-term potentiation (39) and following hippocampal lesion (40) in an NMDA-dependent manner. Furthermore, activin regulates neurotransmitter phenotype of sympathetic neurons (6, 7) . Thus, it is likely that activin regulates neurotransmission by controlling neurotransmitter release from the presynaptic neuron and/or by influencing the efficacy of postsynaptic transmission, leading to the formation of active synapses and the acquisition of learning and memory.
Our characterization of ARIP1 as the scaffold of a complex of activin receptors and a Smad protein in neuronal cells not only presents a novel mode of regulation of receptor serine/threonine kinases but will also help to clarify the neuronal functions of activins and other members of the TGF-␤ family.
